You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

August 28, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Opioid use common among disabled workers enrolled in Medicare

Almost half of disabled workers enrolled in Medicare's prescription drug program fill a prescription for opioids each year, and more than 1 in 5 were chronic users, filling 6 or more opioid prescriptions each year, according to a study.
» Find out how opioids are used in this population

FDA approves diclofenac for managing OA pain

FDA has approved diclofenac (Zorvolex, Iroko Pharmaceuticals) capsules, a nonsteroidal anti-inflammatory drug, for the management of osteoarthritis pain.
» Read more about this new indication for diclofenac

Continuing Education

MTM essentials for atrial fibrillation and drug-induced arrhythmia management

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review current clinical practice guidelines related to atrial fibrillation.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT09-ZXT88.


Announcement: Starting this month, our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA approves apixaban for treatment of DVT, PE

FDA has approved apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as VTE. » Full article

 

Related Articles

High-risk opioid users spend 3 times more

Investigational drug in phase 3 study has potential to be first DMARD for knee osteoarthritis

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group